A Pilot Study in Patients Treated With MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Trial Profile

A Pilot Study in Patients Treated With MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Ferumoxytol (Primary) ; Irinotecan (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Ipsen; Merrimack Pharmaceuticals
  • Most Recent Events

    • 22 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Oct 2017, according to ClinicalTrials.gov record.
    • 22 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jun 2017, according to ClinicalTrials.gov record.
    • 12 Dec 2015 Trial design presented at the 38th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top